## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				TEN	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										Estima	OMB Number: 3235- Estimated average burden hours per response:				
1. Name and Address of Reporting Person* Ramaswamy Vivek						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Roivant Sciences Ltd.</u> [ ROIV ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 05/27/2023									Officer (give title Other (specify below) below)						
	PO BOX 20860				4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) COLUMB	MBUS OH 43220				Form filed by More than One Reporting Person   Rule 10b5-1(c) Transaction Indication															
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Т	able I - No	on-De	erivati	ve S	Secu	urities Acc	quired,	Dis	posed of	, or Ber	neficially C	Owned						
Date					ate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) ( Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficially Following		Form	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) oi (D)	r Price	Reported Transaction (Instr. 3 and	n(s) d 4)			(Instr. 4)		
Common Shares 05/2					/27/20	27/2023			<b>M</b> <sup>(1)</sup>		382,20	3 A	(1)	54,791,414 <sup>(5)</sup>			D			
Common Shares 05/3						5/31/2023			J <sup>(2)</sup>		189,94	7 D	<b>\$9.09</b> <sup>(3)</sup>	9 <sup>(3)</sup> 54,601,467 <sup>(5)</sup>			D			
			Table II -					ities Acqu warrants,	,		,		ficially Ov rities)	vned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/ <sup>\</sup>	· ·	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Yea		ate	Securities	nd Amount of s Underlying e Security nd 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownershin Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownersh (Instr. 4)		
					Code	de V		(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)					
Capped Value Appreciation	(1)(4)	05/27/2023			М			1,222,787 <sup>(1)</sup>	(1)		03/31/2026	Common Shares	382,203(1)	\$6.4 <sup>(1)</sup>	8,559,5	505 <sup>(4)</sup>	D			

## Explanation of Responses:

Appreciation Rights

1. Reflects the conversion of 1,222,787 capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at \$12.68 per share) as of the relevant date of determination over (B) the hurdle price of \$6.40 per share (such excess, the "CVAR Amount"). On May 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 382,203 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023.

2. Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's "sell to cover" policy and does not represent a discretionary sale by the reporting person.

3. The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$8.95 to \$9.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

4. In the event the fair market value of a Common Share is less than \$9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs.

5. Includes an award of restricted stock covering Common Shares that is fully vested.

/s/ Vivek Ramaswamy 05/31/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.